Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (12): 1160-1166.DOI: 10.3969/j.issn.1673-8640.2023.12.010
Previous Articles Next Articles
WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin()
Received:
2023-03-14
Revised:
2023-09-26
Online:
2023-12-30
Published:
2024-02-20
CLC Number:
WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia[J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.12.010
组别 | 例数 | 性别 | 年龄 | 白细胞计数 | TP53 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | <50岁/[例(%)] | ≥50岁/[例(%)] | <100×109/L/[例(%)] | ≥100×109/L/[例(%)] | 阴性/[例(%)] | 阳性/[例(%)] | |||||||||||||
复发组 | 25 | 16(64.0) | 9(36.0) | 16(64.0) | 9(36.0) | 19(76.0) | 6(24.0) | 19(76.0) | 6(24.0) | |||||||||||
未复发组 | 107 | 59(55.1) | 48(44.9) | 74(69.2) | 33(30.8) | 96(89.7) | 11(10.3) | 99(92.5) | 8(7.5) | |||||||||||
χ2值 | 0.648 | 0.249 | 2.287 | 4.223 | ||||||||||||||||
P值 | 0.421 | 0.618 | 0.130 | 0.040 | ||||||||||||||||
组别 | 染色体 | 移殖前状态 | 化疗缓解疗程 | HLA相合程度 | 清髓方案 | |||||||||||||||
正常/[例(%)] | 异常/[例(%)] | CR/[例(%)] | NR/[例(%)] | CR1①/[例(%)] | >CR1②/[例(%)] | 全相合/[例(%)] | 半相合/[例(%)] | MAC/[例(%)] | RIC/[例(%)] | |||||||||||
复发组 | 17(68.0) | 8(32.0) | 14(56.0) | 11(44.0) | 12(48.0) | 13(52.0) | 11(44.0) | 14(56.0) | 22(88.0) | 3(12.0) | ||||||||||
未复发组 | 65(60.7) | 42(39.3) | 87(81.3) | 20(18.7) | 71(66.4) | 36(33.6) | 52(48.6) | 55(51.4) | 81(75.7) | 26(24.3) | ||||||||||
χ2值 | 0.453 | 7.223 | 2.925 | 0.172 | 1.788 | |||||||||||||||
P值 | 0.501 | 0.007 | 0.087 | 0.679 | 0.181 | |||||||||||||||
组别 | 血型 | CMV感染 | cGVHD | aGVHD | ||||||||||||||||
相合/[例(%)] | 不相合/[例(%)] | 无/[例(%)] | 有/[例(%)] | 无/[例(%)] | 有/[例(%)] | 无/[例(%)] | 有/[例(%)] | |||||||||||||
复发组 | 10(40.0) | 15(60.0) | 22(88.0) | 3(12.0) | 22(88.0) | 3(12.0) | 17(68.0) | 8(32.0) | ||||||||||||
未复发组 | 50(46.7) | 57(53.3) | 78(72.9) | 29(27.1) | 93(86.9) | 14(13.1) | 85(79.4) | 22(20.6) | ||||||||||||
χ2值 | 0.370 | 2.517 | 0 | 1.510 | ||||||||||||||||
P值 | 0.543 | 0.113 | 1 | 0.219 |
组别 | 例数 | 性别 | 年龄 | 白细胞计数 | TP53 | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男/[例(%)] | 女/[例(%)] | <50岁/[例(%)] | ≥50岁/[例(%)] | <100×109/L/[例(%)] | ≥100×109/L/[例(%)] | 阴性/[例(%)] | 阳性/[例(%)] | |||||||||||||
复发组 | 25 | 16(64.0) | 9(36.0) | 16(64.0) | 9(36.0) | 19(76.0) | 6(24.0) | 19(76.0) | 6(24.0) | |||||||||||
未复发组 | 107 | 59(55.1) | 48(44.9) | 74(69.2) | 33(30.8) | 96(89.7) | 11(10.3) | 99(92.5) | 8(7.5) | |||||||||||
χ2值 | 0.648 | 0.249 | 2.287 | 4.223 | ||||||||||||||||
P值 | 0.421 | 0.618 | 0.130 | 0.040 | ||||||||||||||||
组别 | 染色体 | 移殖前状态 | 化疗缓解疗程 | HLA相合程度 | 清髓方案 | |||||||||||||||
正常/[例(%)] | 异常/[例(%)] | CR/[例(%)] | NR/[例(%)] | CR1①/[例(%)] | >CR1②/[例(%)] | 全相合/[例(%)] | 半相合/[例(%)] | MAC/[例(%)] | RIC/[例(%)] | |||||||||||
复发组 | 17(68.0) | 8(32.0) | 14(56.0) | 11(44.0) | 12(48.0) | 13(52.0) | 11(44.0) | 14(56.0) | 22(88.0) | 3(12.0) | ||||||||||
未复发组 | 65(60.7) | 42(39.3) | 87(81.3) | 20(18.7) | 71(66.4) | 36(33.6) | 52(48.6) | 55(51.4) | 81(75.7) | 26(24.3) | ||||||||||
χ2值 | 0.453 | 7.223 | 2.925 | 0.172 | 1.788 | |||||||||||||||
P值 | 0.501 | 0.007 | 0.087 | 0.679 | 0.181 | |||||||||||||||
组别 | 血型 | CMV感染 | cGVHD | aGVHD | ||||||||||||||||
相合/[例(%)] | 不相合/[例(%)] | 无/[例(%)] | 有/[例(%)] | 无/[例(%)] | 有/[例(%)] | 无/[例(%)] | 有/[例(%)] | |||||||||||||
复发组 | 10(40.0) | 15(60.0) | 22(88.0) | 3(12.0) | 22(88.0) | 3(12.0) | 17(68.0) | 8(32.0) | ||||||||||||
未复发组 | 50(46.7) | 57(53.3) | 78(72.9) | 29(27.1) | 93(86.9) | 14(13.1) | 85(79.4) | 22(20.6) | ||||||||||||
χ2值 | 0.370 | 2.517 | 0 | 1.510 | ||||||||||||||||
P值 | 0.543 | 0.113 | 1 | 0.219 |
病例 | 性别 | 年龄/岁 | 原发病 | 初诊白细胞计数/(×109/L) | TP53突变情况 | 移植前缓解状态 | 复发部位 | 复发时间/月 | 复发后主要治疗 | 转归 |
---|---|---|---|---|---|---|---|---|---|---|
1 | 男 | 39 | M4 | <100 | 无 | NR | 骨髓 | 5 | 化疗+供者淋巴细胞输注 | 未知 |
2 | 女 | 51 | M5 | <100 | 无 | CR | 骨髓 | 5 | 化疗+供者淋巴细胞输注 | 死亡 |
3 | 女 | 63 | M0 | <100 | 有 | NR | 骨髓 | 3 | 对症/支持 | 死亡 |
4 | 男 | 51 | M5 | <100 | 无 | NR | 骨髓 | 10 | 化疗+对症/支持治疗 | 死亡 |
5 | 女 | 43 | M4 | <100 | 有 | CR | 骨髓 | 3 | 放弃治疗 | 未知 |
6 | 女 | 58 | M2 | <100 | 无 | CR | 中枢神经系统 | 3 | 化疗+放疗 | 未知 |
7 | 男 | 29 | M4 | <100 | 无 | CR | 骨髓 | 2 | 化疗+供者淋巴细胞输注 | 未知 |
8 | 男 | 59 | AML | <100 | 有 | NR | 骨髓 | 2 | 对症/支持治疗 | 死亡 |
9 | 男 | 30 | M4 | <100 | 无 | CR | 骨髓 | 6 | 二次移植 | 未知 |
10 | 女 | 51 | M5 | ≥100 | 无 | CR | 骨髓 | 5 | 化疗+对症/支持治疗 | 未知 |
11 | 男 | 55 | M5 | <100 | 有 | NR | 骨髓 | 5 | 放弃治疗 | 未知 |
12 | 男 | 53 | AML | <100 | 无 | NR | 骨髓 | 6 | 放弃治疗 | 未知 |
13 | 女 | 41 | M5 | ≥100 | 无 | NR | 骨髓 | 4 | 化疗+供者淋巴细胞输注 | 未知 |
14 | 男 | 16 | M4 | ≥100 | 无 | CR | 骨髓 | 4 | 二次移植 | 死亡 |
15 | 男 | 18 | M4 | ≥100 | 无 | NR | 骨髓 | 5 | 化疗+对症/支持治疗 | |
16 | 女 | 16 | M2 | <100 | 无 | NR | 骨髓 | 3 | 化疗+供者淋巴细胞输注 | 未知 |
17 | 男 | 45 | M5 | <100 | 无 | NR | 左肩部 | 11 | 化疗+对症/支持治疗 | 未知 |
18 | 男 | 40 | M5 | <100 | 有 | CR | 骨髓 | 7 | 二次移植 | 存活 |
19 | 女 | 52 | M5 | <100 | 有 | CR | 盆腔 | 10 | 化疗+对症/支持治疗 | 未知 |
20 | 男 | 37 | M2 | ≥100 | 无 | CR | 骨髓 | 6 | 化疗+对症/支持治疗 | 未知 |
21 | 男 | 33 | M4 | ≥100 | 无 | CR | 骨髓 | 4 | 化疗+供者淋巴细胞输注 | 未知 |
22 | 女 | 47 | M5 | <100 | 无 | CR | 骨髓 | 24 | 二次移植 | 死亡 |
23 | 男 | 36 | M5 | <100 | 无 | NR | 骨髓 | 3 | 化疗+对症/支持治疗 | |
24 | 男 | 32 | AMLL | <100 | 无 | CR | 骨髓 | 30 | 化疗+对症/支持治疗 | 存活 |
25 | 男 | 29 | M4 | <100 | 无 | CR | 骨髓 | 14 | 二次移植 | 存活 |
病例 | 性别 | 年龄/岁 | 原发病 | 初诊白细胞计数/(×109/L) | TP53突变情况 | 移植前缓解状态 | 复发部位 | 复发时间/月 | 复发后主要治疗 | 转归 |
---|---|---|---|---|---|---|---|---|---|---|
1 | 男 | 39 | M4 | <100 | 无 | NR | 骨髓 | 5 | 化疗+供者淋巴细胞输注 | 未知 |
2 | 女 | 51 | M5 | <100 | 无 | CR | 骨髓 | 5 | 化疗+供者淋巴细胞输注 | 死亡 |
3 | 女 | 63 | M0 | <100 | 有 | NR | 骨髓 | 3 | 对症/支持 | 死亡 |
4 | 男 | 51 | M5 | <100 | 无 | NR | 骨髓 | 10 | 化疗+对症/支持治疗 | 死亡 |
5 | 女 | 43 | M4 | <100 | 有 | CR | 骨髓 | 3 | 放弃治疗 | 未知 |
6 | 女 | 58 | M2 | <100 | 无 | CR | 中枢神经系统 | 3 | 化疗+放疗 | 未知 |
7 | 男 | 29 | M4 | <100 | 无 | CR | 骨髓 | 2 | 化疗+供者淋巴细胞输注 | 未知 |
8 | 男 | 59 | AML | <100 | 有 | NR | 骨髓 | 2 | 对症/支持治疗 | 死亡 |
9 | 男 | 30 | M4 | <100 | 无 | CR | 骨髓 | 6 | 二次移植 | 未知 |
10 | 女 | 51 | M5 | ≥100 | 无 | CR | 骨髓 | 5 | 化疗+对症/支持治疗 | 未知 |
11 | 男 | 55 | M5 | <100 | 有 | NR | 骨髓 | 5 | 放弃治疗 | 未知 |
12 | 男 | 53 | AML | <100 | 无 | NR | 骨髓 | 6 | 放弃治疗 | 未知 |
13 | 女 | 41 | M5 | ≥100 | 无 | NR | 骨髓 | 4 | 化疗+供者淋巴细胞输注 | 未知 |
14 | 男 | 16 | M4 | ≥100 | 无 | CR | 骨髓 | 4 | 二次移植 | 死亡 |
15 | 男 | 18 | M4 | ≥100 | 无 | NR | 骨髓 | 5 | 化疗+对症/支持治疗 | |
16 | 女 | 16 | M2 | <100 | 无 | NR | 骨髓 | 3 | 化疗+供者淋巴细胞输注 | 未知 |
17 | 男 | 45 | M5 | <100 | 无 | NR | 左肩部 | 11 | 化疗+对症/支持治疗 | 未知 |
18 | 男 | 40 | M5 | <100 | 有 | CR | 骨髓 | 7 | 二次移植 | 存活 |
19 | 女 | 52 | M5 | <100 | 有 | CR | 盆腔 | 10 | 化疗+对症/支持治疗 | 未知 |
20 | 男 | 37 | M2 | ≥100 | 无 | CR | 骨髓 | 6 | 化疗+对症/支持治疗 | 未知 |
21 | 男 | 33 | M4 | ≥100 | 无 | CR | 骨髓 | 4 | 化疗+供者淋巴细胞输注 | 未知 |
22 | 女 | 47 | M5 | <100 | 无 | CR | 骨髓 | 24 | 二次移植 | 死亡 |
23 | 男 | 36 | M5 | <100 | 无 | NR | 骨髓 | 3 | 化疗+对症/支持治疗 | |
24 | 男 | 32 | AMLL | <100 | 无 | CR | 骨髓 | 30 | 化疗+对症/支持治疗 | 存活 |
25 | 男 | 29 | M4 | <100 | 无 | CR | 骨髓 | 14 | 二次移植 | 存活 |
项目 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
OR①值 | 95%CI② | P值 | OR值 | 95%CI | P值 | ||
性别 | 0.694 | 0.307~1.572 | 0.381 | ||||
年龄 | 1.336 | 0.603~3.091 | 0.455 | ||||
白细胞计数 | 2.559 | 1.019~6.427 | 0.046 | 2.894 | 1.116~7.504 | 0.029 | |
TP53基因突变 | 3.612 | 1.439~9.069 | 0.006 | 3.331 | 1.310~8.471 | 0.012 | |
染色体 | 0.765 | 0.330~1.773 | 0.533 | ||||
移植前状态 | 3.217 | 1.457~7.105 | 0.004 | 2.541 | 1.088~5.933 | 0.031 | |
化疗缓解疗程 | 1.990 | 0.907~4.364 | 0.086 | 1.728 | 0.731~4.086 | 0.213 | |
HLA | 1.198 | 0.544~2.639 | 0.655 | ||||
清髓方案 | 0.455 | 0.136~1.520 | 0.201 | ||||
血型 | 1.230 | 0.553~2.739 | 0.612 | ||||
CMV 感染 | 0.409 | 0.122~1.367 | 0.146 | ||||
cGVHD | 0.897 | 0.268~2.998 | 0.860 | ||||
aGVHD | 1.718 | 0.741~3.985 | 0.207 |
项目 | 单因素分析 | 多因素分析 | |||||
---|---|---|---|---|---|---|---|
OR①值 | 95%CI② | P值 | OR值 | 95%CI | P值 | ||
性别 | 0.694 | 0.307~1.572 | 0.381 | ||||
年龄 | 1.336 | 0.603~3.091 | 0.455 | ||||
白细胞计数 | 2.559 | 1.019~6.427 | 0.046 | 2.894 | 1.116~7.504 | 0.029 | |
TP53基因突变 | 3.612 | 1.439~9.069 | 0.006 | 3.331 | 1.310~8.471 | 0.012 | |
染色体 | 0.765 | 0.330~1.773 | 0.533 | ||||
移植前状态 | 3.217 | 1.457~7.105 | 0.004 | 2.541 | 1.088~5.933 | 0.031 | |
化疗缓解疗程 | 1.990 | 0.907~4.364 | 0.086 | 1.728 | 0.731~4.086 | 0.213 | |
HLA | 1.198 | 0.544~2.639 | 0.655 | ||||
清髓方案 | 0.455 | 0.136~1.520 | 0.201 | ||||
血型 | 1.230 | 0.553~2.739 | 0.612 | ||||
CMV 感染 | 0.409 | 0.122~1.367 | 0.146 | ||||
cGVHD | 0.897 | 0.268~2.998 | 0.860 | ||||
aGVHD | 1.718 | 0.741~3.985 | 0.207 |
临床资料 | 2年RFS率/ [%,M(95%CI)] | χ2值 | P值 | 临床资料 | 2年RFS率/ [%,M(95%CI)] | χ2值 | P值 |
---|---|---|---|---|---|---|---|
性别 | 0.789 | 0.374 | HLA | 0.204 | 0.651 | ||
男性 | 78.60(68.996~88.204) | 全相合 | 81.80(72.000~91.600) | ||||
女性 | 84.00(74.396~93.604) | 半相合 | 80.20(70.596~89.804) | ||||
年龄 | 0.574 | 0.449 | 清髓方案 | 1.757 | 0.185 | ||
<50岁 | 83.00(75.160~90.840) | MAC | 77.70(69.468~85.932) | ||||
≥50岁 | 76.20(62.676~89.724) | RIC | 87.40(73.680~101.120) | ||||
白细胞计数 | 4.385 | 0.036 | 血型 | 0.264 | 0.608 | ||
<100×109/L | 83.70(76.840~90.560) | 相合 | 82.70(72.900~92.500) | ||||
≥100×109/L | 61.90(37.792~86.008) | 不相合 | 92.90(70.292~879.108) | ||||
TP53基因突变 | 8.731 | 0.003 | CMV感染 | 2.295 | 0.130 | ||
阴性 | 84.10(77.436~90.764) | 无 | 78.40(70.168~86.632) | ||||
阳性 | 52.20(24.172~80.228) | 有 | 89.60(78.428~100.772) | ||||
染色体 | 0.399 | 0.528 | cGVHD | 0.032 | 0.859 | ||
正常 | 79.20(70.184~88.216) | 无 | 80.90(73.452~88.348) | ||||
异常 | 83.80(73.412~94.188) | 有 | 80.90(61.300~100.500) | ||||
移植前状态 | 9.527 | 0.002 | aGVHD | 1.662 | 0.197 | ||
CR | 86.70(79.840~93.560) | 无 | 83.80(76.548~91.052) | ||||
NR | 73.30(60.168~86.432) | 有 | 70.30(52.856~87.744) | ||||
化疗缓解疗程 | 3.122 | 0.077 | |||||
CR1① | 85.20(77.556~92.844) | ||||||
>CR1② | 69.60(55.292~83.908) |
临床资料 | 2年RFS率/ [%,M(95%CI)] | χ2值 | P值 | 临床资料 | 2年RFS率/ [%,M(95%CI)] | χ2值 | P值 |
---|---|---|---|---|---|---|---|
性别 | 0.789 | 0.374 | HLA | 0.204 | 0.651 | ||
男性 | 78.60(68.996~88.204) | 全相合 | 81.80(72.000~91.600) | ||||
女性 | 84.00(74.396~93.604) | 半相合 | 80.20(70.596~89.804) | ||||
年龄 | 0.574 | 0.449 | 清髓方案 | 1.757 | 0.185 | ||
<50岁 | 83.00(75.160~90.840) | MAC | 77.70(69.468~85.932) | ||||
≥50岁 | 76.20(62.676~89.724) | RIC | 87.40(73.680~101.120) | ||||
白细胞计数 | 4.385 | 0.036 | 血型 | 0.264 | 0.608 | ||
<100×109/L | 83.70(76.840~90.560) | 相合 | 82.70(72.900~92.500) | ||||
≥100×109/L | 61.90(37.792~86.008) | 不相合 | 92.90(70.292~879.108) | ||||
TP53基因突变 | 8.731 | 0.003 | CMV感染 | 2.295 | 0.130 | ||
阴性 | 84.10(77.436~90.764) | 无 | 78.40(70.168~86.632) | ||||
阳性 | 52.20(24.172~80.228) | 有 | 89.60(78.428~100.772) | ||||
染色体 | 0.399 | 0.528 | cGVHD | 0.032 | 0.859 | ||
正常 | 79.20(70.184~88.216) | 无 | 80.90(73.452~88.348) | ||||
异常 | 83.80(73.412~94.188) | 有 | 80.90(61.300~100.500) | ||||
移植前状态 | 9.527 | 0.002 | aGVHD | 1.662 | 0.197 | ||
CR | 86.70(79.840~93.560) | 无 | 83.80(76.548~91.052) | ||||
NR | 73.30(60.168~86.432) | 有 | 70.30(52.856~87.744) | ||||
化疗缓解疗程 | 3.122 | 0.077 | |||||
CR1① | 85.20(77.556~92.844) | ||||||
>CR1② | 69.60(55.292~83.908) |
[1] |
DE KOUCHKOVSKY I, ABDUL-HAY M. Acute myeloid leukemia:a comprehensive review and 2016 update[J]. Blood Cancer J, 2016, 6(7):e441.
DOI |
[2] |
TSIRIGOTIS P, BYRNE M, SCHMID C, et al. Relapse of AML after hematopoietic stem cell transplantation:methods of monitoring and preventive strategies. A review from the ALWP of the EBMT[J]. Bone Marrow Transplant, 2016, 51(11):1431-1438.
DOI |
[3] |
BAZARBACHIA, SCHMID C, LABOPIN M, et al. Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years[J]. Clin Cancer Res, 2020, 26(24):6475-6482.
DOI PMID |
[4] |
HOROWITZ M, SCHREIBER H, ELDER A, et al. Epidemiology and biology of relapse after stem cell transplantation[J]. Bone Marrow Transplant, 2018, 53(11):1379-1389.
DOI |
[5] | MCGOWAN-JORDAN J, SIMONS A, SCHMID M. ISCN 2016:an international system for human cytogenomic nomenclature(2016)[M]. Basel:Karger, 2016. |
[6] |
ALI A M, MIRRAKHIMOV A E, ABBOUD C N, et al. Leukostasis in adult acute hyperleukocytic leukemia:a clinician's digest[J]. Hematol Oncol, 2016, 34(2):69-78.
DOI URL |
[7] |
BEWERSDORF J P, ZEIDAN A M. Hyperleukocytosis and leukostasis in acute myeloid leukemia:can a better understanding of the underlying molecular pathophysiology leadto novel treatments?[J]. Cells, 2020, 9(10):2310.
DOI URL |
[8] |
FENG S, ZHOU L, ZHANG X, et al. Impact of ELN risk stratification,induction chemotherapy regimens and hematopoietic stem cell transplantation on outcomes in hyperleukocytic acute myeloid leukemia with initial white blood cell count more than 100×109/L[J]. Cancer Manag Res, 2019, 11:9495-9503.
DOI URL |
[9] |
VENTURA G J, HESTER J P, SMITH T L, et al. Acute myeloblastic leukemia with hyperleukocytosis:risk factors for early mortality in induction[J]. Am J Hematol, 1988, 27(1):34-37.
DOI URL |
[10] |
RÖLLIG C, EHNINGER G. How I treat hyperleukocytosis in acute myeloid leukemia[J]. Blood, 2015, 125(21):3246-3252.
DOI PMID |
[11] |
CANAANI J, LABOPIN M, SOCIE G, et al. Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation:an analysis from the acute leukemia working party of the EBMT[J]. Am J Hematol, 2017, 92(7):653-659.
DOI URL |
[12] | 丁文稳. 异基因造血干细胞移植后急性白血病复发的危险因素分析[D]. 郑州: 郑州大学, 2019. |
[13] |
STENGEL A, KERN W, HAFERLACH T, et al. The impact of TP53 mutations and TP53 deletions on survival varies between AML,ALL,MDS and CLL:an analysis of 3 307 cases[J]. Leukemia, 2017, 31(3):705-711.
DOI URL |
[14] |
WELCH J S. Patterns of mutations in TP53 mutated AML[J]. Best Pract Res Clin Haematol, 2018, 31(4):379-383.
DOI PMID |
[15] | BLUM W, BOLWELL B, PHILLIPS G, et al. High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation[J]. Biol Blood Marrow Transplant, 2006, 12(1):61-67. |
[16] | LIN C H, CHEN T C, SHIH Y H, et al. Acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation:a retrospective study from a single institution[J]. J Int Med Res, 2022, 50(2):3000605221078466. |
[1] | FU Yi, YANG Xuesong, JIN Ligang, ZHAI Hongli, JIN Xiaoling. Correlation between small and dense low-density lipoprotein cholesterol and acute coronary syndrome with the occurrence of long-term adverse cardiovascular events [J]. Laboratory Medicine, 2023, 38(9): 878-883. |
[2] | SU Xi, ZHOU Yan, HUANG Jian, GAO Yaoyi, LI Yihao, WANG Beili, PAN Baishen, GUO Wei. Effect of CYP3A4 *1G polymorphism on fentanyl in patients undergoing laparoscopic radical resection of colorectal cancer [J]. Laboratory Medicine, 2023, 38(5): 419-423. |
[3] | WANG Ruijuan, LI Chao, DUAN Lijuan, SHANG Miao, YANG Ruyu. Expression and clinical significance of lncRNA RBM5-AS1 in acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(1): 39-45. |
[4] | CHEN Yuemei, JIN Yongmei, ZENG Tingting, JIANG Nenggang, LIAO Hongyan. Diagnosis and clinical characteristics of acute myeloid leukemia with BCR-ABL1 accompanied by FLT3-ITD and multiple gene mutations [J]. Laboratory Medicine, 2022, 37(4): 365-369. |
[5] | WU Wenping, XU Linjuan, WANG Jiaheng, ZHANG Nana. Correlation analysis of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia [J]. Laboratory Medicine, 2022, 37(11): 1017-1022. |
[6] | LE Jiangman, LI Tianyuan, TAN Meiyu, WANG Yajie, ZHOU Lida, SHU Jie, WU Jiaoxiang, SUN Hanxiao, XUAN Binbin, CAI Xushan, SHENG Huiming. Correlation of gestational diabetes mellitus with plasma TMAO [J]. Laboratory Medicine, 2021, 36(8): 795-799. |
[7] | HUANG Xiaofeng, FAN Xueming, YAO Tianyue, YUAN Wenhua, ZHAO Zhiyun, SONG Yunxiao. Correlation between red cell distribution width and prostate cancer [J]. Laboratory Medicine, 2021, 36(6): 590-595. |
[8] | PENG Xinguo, SUN Changhua, AN Jiajia, CUI Yanfang, DONG Yan, WANG Jian, GAO Meilan. Immune reconstitution after allogeneic hematopoietic stem cell transplantation and its correlation with fungal infection [J]. Laboratory Medicine, 2020, 35(5): 447-450. |
[9] | WANG Junjie, YAO Zonghui, MA Bing, LI Yi, YAN Wenjuan, WANG Shanmei, MA Qiong, YUAN Youhua. Risk factors and prognosis of bloodstream infection caused by carbapenem-resistant Klebsiella pneumoniae [J]. Laboratory Medicine, 2020, 35(3): 195-199. |
[10] | DING Jing, LIU Weiling, WAN Liping, LI Li, BAI Ping. Analysis on hemophagocytic phenomenon after allogeneic hematopoietic stem cell transplantation [J]. Laboratory Medicine, 2020, 35(3): 251-255. |
[11] | LIU Sijia, CHENG Feng, WU Yayun, LI Zhenyu, GONG Guofu, DUAN Xiuqun, CHEN Shengli. Analysis of laboratory indexes and risk factors of patients with severe Corona Virus Disease 2019 [J]. Laboratory Medicine, 2020, 35(12): 1229-1233. |
[12] | Xi'an YANG Jian, ZHANG Tianhua, XIAN Xiaoping, LI Yan, CHEN Meiling, WANG Rui. Drug resistance of 218 isolates of Mycobacterium tuberculosis in [J]. Laboratory Medicine, 2019, 34(5): 421-427. |
[13] | LI Jing, LIU Xuechao, SUN Huimin, CUI Bingyi, LIU Xiuwei. Multiple drug resistant infection in patients with nosocomial bacterial pneumonia and risk factors for death within 30 d [J]. Laboratory Medicine, 2019, 34(4): 300-304. |
[14] | LU Taohong, ZHANG Qingfang, ZHU Xiaoli, YUAN Dandan, LI Xin. Clinical characteristics,isolation rate and drug resistance of Stenotrophomonas maltophilia [J]. Laboratory Medicine, 2018, 33(6): 525-529. |
[15] | LI Jinghua, ZHAO Wei, TONG Jingjing, ZHANG Tie, CAO Yongtong. Risk factors of decompensated liver cirrhosis in primary biliary cirrhosis [J]. Laboratory Medicine, 2018, 33(5): 399-403. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||